{"id":4134,"date":"2024-10-11T10:15:58","date_gmt":"2024-10-11T10:15:58","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/"},"modified":"2026-01-22T14:41:17","modified_gmt":"2026-01-22T14:41:17","slug":"radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/","title":{"rendered":"Radiotherapy improves efficacy of the PARP inhibitor Niraparib in a preclinical model of triple negative breast cancer"},"content":{"rendered":"<p>PARP inhibitors represent a powerful class of cancer therapies that target poly-ADP-ribose polymerase (PARP)- a key enzyme in DNA repair. In triple-negative breast cancer (TNBC), where cells often have defects in the homologous recombination (HR) DNA repair pathway, PARP inhibitors offer a strategic vulnerability.<\/p>\n<p>This poster from Sygnature Discovery explores how combining niraparib, a clinically approved PARP inhibitor, with radiotherapy further exploits this vulnerability to increase therapeutic efficacy in a preclinical TNBC model.<\/p>\n<h3>Scientific Background<\/h3>\n<p>PARP inhibitors work by interfering with base excision repair, which becomes critical in HR-deficient cells. Without functional HR, these cells accumulate unrepaired double-strand breaks- particularly after exposure to DNA-damaging treatments like radiotherapy.<\/p>\n<p>By combining PARPi with radiation, the synergy increases DNA damage beyond repair, promoting cell death and enhancing tumour control. This combination strategy holds promise for improving outcomes in hard-to-treat cancers like TNBC.<\/p>\n<h3>Translating Mechanism into Efficacy<\/h3>\n<p>Sygnature Discovery provides full-service support for DNA damage response and radiotherapy combination strategies- from<em> in vitro<\/em> assessment to preclinical <a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/in-vivo-pharmacology-and-in-vivo-testing\/\"><em>in vivo<\/em> modelling<\/a>&#8211; helping partners build stronger oncology pipelines.<\/p>\n<p><a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/in-vivo-pharmacology-and-in-vivo-testing\/\">Speak to our oncology experts<\/a> to explore how we can support your next DDR or radiotherapy combination project.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":2868,"template":"","category":[740,685,751,738,688],"class_list":["post-4134","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-ex-vivo-tissue-analysis","category-in-vivo-pharmacology","category-oncology","category-oncology-models","category-therapeutic-areas"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Radiotherapy &amp; PARP Inhibition in TNBC<\/title>\n<meta name=\"description\" content=\"Download Sygnature Discovery&#039;s poster exploring the enhanced efficacy of PARP inhibitors combined with radiotherapy in a TNBC model.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Radiotherapy &amp; PARP Inhibition in TNBC\" \/>\n<meta property=\"og:description\" content=\"Download Sygnature Discovery&#039;s poster exploring the enhanced efficacy of PARP inhibitors combined with radiotherapy in a TNBC model.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T14:41:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/A0-poster-EORTC-2024-final-blur-e1744716804383.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"444\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/\",\"url\":\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/\",\"name\":\"Radiotherapy & PARP Inhibition in TNBC\",\"isPartOf\":{\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/A0-poster-EORTC-2024-final-blur-e1744716804383.jpg\",\"datePublished\":\"2024-10-11T10:15:58+00:00\",\"dateModified\":\"2026-01-22T14:41:17+00:00\",\"description\":\"Download Sygnature Discovery's poster exploring the enhanced efficacy of PARP inhibitors combined with radiotherapy in a TNBC model.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#primaryimage\",\"url\":\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/A0-poster-EORTC-2024-final-blur-e1744716804383.jpg\",\"contentUrl\":\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/A0-poster-EORTC-2024-final-blur-e1744716804383.jpg\",\"width\":444,\"height\":628,\"caption\":\"||\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Radiotherapy improves efficacy of the PARP inhibitor Niraparib in a preclinical model of triple negative breast cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/#website\",\"url\":\"https:\/\/www.sygnaturediscovery.com\/fr\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/#organization\",\"name\":\"Sygnature Discovery\",\"url\":\"https:\/\/www.sygnaturediscovery.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg\",\"contentUrl\":\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Radiotherapy & PARP Inhibition in TNBC","description":"Download Sygnature Discovery's poster exploring the enhanced efficacy of PARP inhibitors combined with radiotherapy in a TNBC model.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/","og_locale":"fr_CA","og_type":"article","og_title":"Radiotherapy & PARP Inhibition in TNBC","og_description":"Download Sygnature Discovery's poster exploring the enhanced efficacy of PARP inhibitors combined with radiotherapy in a TNBC model.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/","og_site_name":"Sygnature","article_modified_time":"2026-01-22T14:41:17+00:00","og_image":[{"width":444,"height":628,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/A0-poster-EORTC-2024-final-blur-e1744716804383.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/","name":"Radiotherapy & PARP Inhibition in TNBC","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/A0-poster-EORTC-2024-final-blur-e1744716804383.jpg","datePublished":"2024-10-11T10:15:58+00:00","dateModified":"2026-01-22T14:41:17+00:00","description":"Download Sygnature Discovery's poster exploring the enhanced efficacy of PARP inhibitors combined with radiotherapy in a TNBC model.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/A0-poster-EORTC-2024-final-blur-e1744716804383.jpg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/A0-poster-EORTC-2024-final-blur-e1744716804383.jpg","width":444,"height":628,"caption":"||"},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/radiotherapy-improves-efficacy-of-the-parp-inhibitor-niraparib-in-a-preclinical-model-of-triple-negative-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Radiotherapy improves efficacy of the PARP inhibitor Niraparib in a preclinical model of triple negative breast cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/4134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/4134\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/2868"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=4134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=4134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}